系统性硬化症试验中报告结局的范围与一致性
该研究检索2000年至2018年的随机试验,评估系统性硬化症(SSc)试验中报告结局的范围与一致性及核心结局集和CRISS的采用情况。从152项试验中归类出4193个结局至84个领域,核心结局集发布后无试验完整报告全部11个领域,CRISS所需5项措施仅11%试验完整报告。结论认为SSc随机试验的结局领域和措施仍很不一致,核心结局集影响甚微。
要点
- 核心结局集发布后无试验完整报告全部11个领域,各领域依从率6.1%至54.4%。
- CRISS所需5项措施仅11%试验完整报告。
- 最常见领域为健康相关生活质量与功能、皮肤、肺部。
核心结论
- 尽管认识到统一采集和报告结局有助于更好评估SSc治疗药物,但SSc随机试验报告的结局领域和措施仍很不一致,核心结局集影响甚微。
研究设计与样本
- 检索Medline、Cochrane Central Register of Controlled Trials、Embase和ClinicalTrials.gov,纳入2000年1月1日至2018年4月29日发表的成人局限型或弥漫型SSc随机试验。
主要发现
- 从152项试验中归类出4193个结局至84个领域。
- 最常见的3个领域为健康相关生活质量与功能(59%,130项措施)、皮肤(47%,59项措施)和肺部(45%,168项措施)。
- 核心结局集发布后,无试验完整报告全部11个领域,各领域依从率6.1%至54.4%,各措施依从率0%至48.1%。
关键数值与推荐
- 核心结局集包含11个领域和31项措施,CRISS所需5项措施在11%的试验中完整报告。
临床怎么用
- 提示临床解读SSc试验证据时需注意结局报告的不一致性,核心结局集和CRISS的采用率仍低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The core outcome set for trials in systemic sclerosis (SSc) was developed in 2008 and comprises 11 domains and 31 measures, leading to the development of the Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS). We aimed to assess the scope and consistency of outcomes reported in trials of SSc and the uptake of this core set and the CRISS. METHODS: Medline, the Cochrane Central Register of Controlled Trials, Embase, and ClinicalTrials.gov were searched to identify randomized trials published from January 1, 2000 to April 29, 2018 in adults with limited or diffuse SSc. Outcomes and measures were recorded for each trial, classified into domains and the frequency of outcomes before after publication of the publication of the core set calculated. RESULTS: From 152 trials, 4,193 outcomes were classified into 84 domains. The 3 most common domains were health-related quality of life (HRQoL) and function (59%, 130 measures), skin (47%, 59 measures), and pulmonary (45%, 168 measures). After the publication of the core outcome set, no trial reported the complete core set with adherence to each of the 11 domains, ranging from 6.1% to 54.4% and adherence to each of the 31 measures ranging from 0% to 48.1%. The 5 measures required for the CRISS were reported completely in 11% of trials. CONCLUSION: Despite recognition that uniform acquisition and reporting of outcomes would enable a better evaluation of proposed SSc therapeutics, the outcome domains and measures reported in randomized trials in SSc remain very inconsistent, with little impact of the core outcome set.
引用
- Sumpton D, Bigot A, Sautenet B, et al. Scope and Consistency of Outcomes Reported in Trials of Patients With Systemic Sclerosis. Arthritis Care Res (Hoboken). 2020. PMID: 31309737. doi:10.1002/acr.24027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。